The combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel-maintained improvements in survival for more than 8 years of follow-up in the first-line treatment of patients with HER2-positive metastatic breast cancer, according to long-term results from the phase III CLEOPATRA study published in theLancet Oncology. This represents the longest known follow-up for this patient population.
HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%, wrote the study authors, led by Sandra M. Swain, MD, FACP, of the Georgetown University Medical Center.
In the study, 808 patients were randomized to receive either placebo plus trastuzumab and docetaxel (n = 406) or pertuzumab in combination with trastuzumab and docetaxel (n = 402). Of the patients enrolled in the intention-to-treat (ITT) population, only 396 in the placebo arm were treated and included in the safety population. In the pertuzumab arm, there were 9 patients who crossed over from the placebo arm who received non-randomized treatment and 2 patients from the pertuzumab arm who did not receive treatment, which left 408 patients in the ITT population for the cohort.
Overall survival (OS) events occurred in 58% of the ITT population who received the placebo combination (n = 235), and in 69% of patients who were given the pertuzumab combination (n = 280). The median OS in the pertuzumab arm was 57.1 months (95% CI, 50-72) versus 40.8 months (95% CI, 36-48) in the placebo group (HR, 0.69; 95% CI, 0.58-0.82).OS was also reviewed in a landmark analysis at 5, 6, 7, and 8 years. The 8-year landmark OS rate, most notably, was 37% (95% CI, 31%-42%) in the pertuzumab group and 23% (95% CI, 19%-28%) in the placebo group.
Progression-free survival (PFS) outcomes were investigator-assessed more than 4 years after data cutoff. The median investigator-assessed PFS observed in the pertuzumab group was 12.4 months (95% CI, 10-14) compared with 18.7 months (95% CI, 17-22) in the placebo group (HR, 0.69; 95% CI, 0.59-0.81), which included 304 PFS events in the pertuzumab arm and 329 in the placebo arm.
The patient subgroups included in the CLEOPATRA study included patients who received prior trastuzumab, as well as patients withPIK3CAwild-type tumors andPIK3CA-mutant tumors. A post-hoc subgroup analysis demonstrated efficacy results that were similar to the overall population. Specifically, individuals who were previously treated with trastuzumab had a median OS of 53.8 months (95% CI, 41-71) in the pertuzumab group and 46.6 months (95% CI, 30-70) in the placebo group (HR, 0.86; 95% CI, 0.51-1.43). This trend was consistent among patients withboth PIK3CAwild-type andPIK3CA-mutant tumors.
Follow treatment in the CLEOPATRA study, 25 patients were enrolled in a pertuzumab extension study (PEREX). Eleven patients from the CLEOPATRA study went on to a post-trial access program, while 23 other patients received ongoing pertuzumab as the standard of care for HER2-positive metastatic breast cancer.
Responses to treatment with pertuzumab in combination with trastuzumab and docetaxel appeared to be durable in this patient population. In total, 99 pertuzumab responders were classified as long-term responders versus only 53 patients who responded to the placebo combination. The durability of responses differed depending on baseline ECOG score, estrogen and progesterone receptor status, HER2 immunohistochemistry status, histological tumor grade, and whether or not patients had previous anthracyclines, radiotherapy, taxanes, or trastuzumab. Notably, in the pertuzumab group, HER2 immunohistochemistry of 3 or higher andPIK3CAmutation showed the largest differences in response.
In terms of safety, the profiles of each drug utilized in the study were consistent with the known safety. Patients treated with pertuzumab had higher incidences of any-grade diarrhea and rash while patients in the placebo arm had higher incidences of grade 3/4 adverse events (AEs). The most common grade 3/4 AE overall was neutropenia, which was observed in 49% of patients in the pertuzumab arm (n = 200) and 46% in the placebo arm (n = 183).
There were 238 patient deaths in the pertuzumab arm prior to crossover. The placebo arm also had 261 deaths, which were predominantly due to disease progression. Eight patients who received pertuzumab and 12 who received placebo died as a result of AEs. The most common death-causing AEs were febrile neutropenia in the pertuzumab group (n = 3) and myocardial infarction in the placebo group (n = 3). Treatment-related deaths were observed in both cohorts with 3 patients experiencing febrile neutropenia, respiratory tract infection, or somnolence in the pertuzumab group and 3 patients experiencing intestinal perforation, pneumonia, sepsis, myocardial infarction, and/or cerebrovascular accident in the placebo group.
Fifty patients from the crossover population died due to either disease progression (24%), metastasis (1%), or an unknown cause (1%).
CLEOPATRA was double-blinded, randomized, and placebo-controlled. Patients in the study were administered the study drugs intravenously every 3 weeks. Pertuzumab was administered at a dose of 840 mg on day 1 of each cycle, as was the matching placebo. The dosage of pertuzumab was decreased to 420 mg in subsequent cycles. Patients received trastuzumab on day 2 of the first cycle, at a dose of 8 mg/kg, which was lowered to 6 mg/kg for subsequent cycles. Docetaxel chemotherapy was administered on day 2 also, at a dose of 75 mg/m2 on the first cycle and 100 mg/m2 for all subsequent cycles.
The study authors noted that historically, the overexpression of HER2 in metastatic breast cancers leads to aggressive disease and poor outcomes. Anti-HER2 monoclonal antibodies like trastuzumab showed promise in other studies as treatment of these patients when added to chemotherapy. However, it was hypothesized that outcomes observed with trastuzumab could be improved upon. The CLEOPATRA study has confirmed this hypothesis.
Reference:
Swain SM, Miles D, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519-530. doi: 10.1016/ S1470-2045(19)30863-0.
Excerpt from:
Pertuzumab Added to Trastuzumab and Chemotherapy Improves Survival in HER2+ Breast Cancer - Targeted Oncology
- ST-Segment Elevation Myocardial Infarction - verywell.com [Last Updated On: May 12th, 2018] [Originally Added On: May 12th, 2018]
- Myocardial infarction (Heart Attack) - Health Facts [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Heart Attack and Acute Coronary Syndrome - Lab Tests Online [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- Myocardial Infarction - ECGpedia [Last Updated On: September 21st, 2018] [Originally Added On: September 21st, 2018]
- Myocardial Infarction Clinical Presentation: History ... [Last Updated On: September 25th, 2018] [Originally Added On: September 25th, 2018]
- Myocardial infarction diagnosis - Wikipedia [Last Updated On: September 25th, 2018] [Originally Added On: September 25th, 2018]
- Myocardial Infarction Treatment & Management: Approach ... [Last Updated On: October 9th, 2018] [Originally Added On: October 9th, 2018]
- Myocardial infarction - Simple English Wikipedia, the free ... [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- ST-Segment Elevation Myocardial Infarction [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- ECG localization of myocardial infarction / ischemia and ... [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- Heart Attack (Myocardial Infarction) Symptoms | Cleveland Clinic [Last Updated On: November 15th, 2018] [Originally Added On: November 15th, 2018]
- Myocardial Infarction (Heart Attack) Ischemia Pathophysiology, ECG, Nursing, Signs, Symptoms Part 1 [Last Updated On: November 15th, 2018] [Originally Added On: November 15th, 2018]
- Myocardial Infarction (MI) NCLEX Questions [Last Updated On: November 30th, 2018] [Originally Added On: November 30th, 2018]
- Myocardial Infarction NCLEX Review (Part 1) [Last Updated On: December 3rd, 2018] [Originally Added On: December 3rd, 2018]
- Acute Myocardial Infarction, Myocardial infection. Patient [Last Updated On: December 4th, 2018] [Originally Added On: December 4th, 2018]
- Heart Attack | Myocardial Infarction | MedlinePlus [Last Updated On: December 16th, 2018] [Originally Added On: December 16th, 2018]
- Heart Attack (Myocardial Infarction) - medicinenet.com [Last Updated On: December 17th, 2018] [Originally Added On: December 17th, 2018]
- Myocardial infarction (acute): Early rule out using high ... [Last Updated On: December 20th, 2018] [Originally Added On: December 20th, 2018]
- Conditions We Treat: Myocardial Infarction | Johns Hopkins ... [Last Updated On: December 23rd, 2018] [Originally Added On: December 23rd, 2018]
- Myocardial Infarction - Heart Home Page [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- Myocardial infarction: signs symptoms and treatment ... [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- ECGs in Acute Myocardial Infarction - ACLS Medical Training [Last Updated On: December 25th, 2018] [Originally Added On: December 25th, 2018]
- Myocardial Infarction - Eccles Health Sciences Library [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Myocardial Infarction: Practice Essentials, Background ... [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Myocardial infarction - Wikipedia [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Nursing Care Plan for Myocardial Infarction | NRSNG [Last Updated On: December 29th, 2018] [Originally Added On: December 29th, 2018]
- Cardiovascular disease - Myocardial infarction | Britannica.com [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Heart Attack (Myocardial Infarction) - Cedars-Sinai [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Top 5 MI ECG Patterns You Must Know | LearntheHeart.com [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Anterior Myocardial Infarction LITFL ECG Library Diagnosis [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Electrocardiography in myocardial infarction - Wikipedia [Last Updated On: January 11th, 2019] [Originally Added On: January 11th, 2019]
- Myocardial Infarction Therapeutics Market, Share, Growth ... [Last Updated On: March 13th, 2019] [Originally Added On: March 13th, 2019]
- Heart Attack (Myocardial Infarction) - Drugs.com [Last Updated On: April 20th, 2019] [Originally Added On: April 20th, 2019]
- STEMI (ST Elevation Myocardial Infarction): diagnosis ... [Last Updated On: April 20th, 2019] [Originally Added On: April 20th, 2019]
- Heart attack - Symptoms and causes - Mayo Clinic [Last Updated On: April 20th, 2019] [Originally Added On: April 20th, 2019]
- Cardiovascular models including myocardial infarction ... [Last Updated On: April 27th, 2019] [Originally Added On: April 27th, 2019]
- Myocardial infarction - Osmosis Video Library [Last Updated On: May 1st, 2019] [Originally Added On: May 1st, 2019]
- Myocardial Infarction [Last Updated On: September 17th, 2019] [Originally Added On: September 17th, 2019]
- Creatinine Rises After RAS Inhibitor Initiation Tied to Worse Outcomes - Renal and Urology News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Ventricular Tachycardia Treatment Market Growth in Technological Innovation, Competitive Landscape Mapping the Trends and Outlook - NewsVarsity [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- FDA Action Alert: Merck and Amarin - BioSpace [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Resverlogix Provides Update on BETonMACE Phase 3 Trial Toronto Stock Exchange:RVX - GlobeNewswire [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Marijuana Use Linked to Improved Acute-HF Hospital Survival - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Population Health vs. Personalized Medicine: Lost in Translation? - American Council on Science and Health [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Bariatric Surgery Tied to Less MACE in Obesity, Diabetes - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- A Novel Algorithm for Improving the Diagnostic Accuracy of Prehospital ST-Elevation Myocardial Infarction - DocWire News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Global Myocardial Infarction Treatment Market Will Reach USD 1726.3 million by end of 2022 - Market News Store [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Frequency and Factors Related to Not Receiving Acute Reperfusion Therapy in Patients with ST Elevation Myocardial Infarction; A Single Specialty... [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Research Offers 10-Year Forecast on Myocardial Infarction Treatment Market - Rapid News Network [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- University of Colorado study suggests Cannabis aids in surviving heart... - Communities Digital News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- SRH part of regional system award recognizing care for heart attacks - Index-Journal [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- TherOx Announces Key SuperSaturated Oxygen Therapy Presentations at TCT 2019 - Yahoo Finance [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Incidence, Characteristics and Outcomes in Very Young Patients with ST Segment Elevation Myocardial Infarction - DocWire News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Health Recovery After Acute MI Similar in Young Adults With and Without Diabetes - The Cardiology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes - Diagnostic and Interventional Cardiology [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Diagnosis of Myocardial Infarction At Autopsy: AECVP Reappraisal in the Light of the Current Clinical Classification - DocWire News [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Global Myocardial Infarction Drug Market 2019 BioCardia, Inc., Biscayne Pharmaceuticals, Inc., Capricor Therapeutics, Inc., Cell - Market News Times [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Abiomed to Highlight Importance of Optimal PCI Treatment to Improve Outcomes for High-Risk Patients at TCT 2019 - Yahoo Finance [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- ENTRUST-AF PCI Supports Safety of Dual Therapy With Edoxaban - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Preoperative opioid use leads to perioperative consequences in foot and ankle surgery - Healio [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- CV, General Safety of Long-Term PPI Use Examined - The Cardiology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Effect of Delayed vs Immediate Interventions in Transient STEMI - The Cardiology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Cardiorenal Disease Is the Most Common CVD Manifestation in Patients With T2D - Endocrinology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- DAPA-HF Published: 'Stunning Consistent Benefit With Dapagliflozin' - Medscape [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Geomagnetic Disturbances and Cardiovascular Mortality Risk - On Health - BMC Blogs Network [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- Reconsidering the Safety of Intravenous Thrombolysis for Ischemic Stroke After Recent Myocardial Infarction - Neurology Advisor [Last Updated On: September 19th, 2019] [Originally Added On: September 19th, 2019]
- The Lowdown on Lipoprotein(a) - Medscape [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Protamine use found to significantly reduce reoperations for patients who undergo carotid endarterectomy - Vascular News [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Left Main Treated With PCI or CABG Have Similar Outcomes at Five Years - Diagnostic and Interventional Cardiology [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sen. Sanders released from the hospital after heart attack - WXYZ [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- E-Selectin Gene Haplotypes are Associated with the Risk of Myocardial Infarction - DocWire News [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients - P&T Community [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Quantitative Flow Ratio guided Residual Functional SYNTAX Score for Risk Assessment in Patients with ST-Segment Elevation Myocardial Infarction... [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Coronary Calcium Scan: The Role of Calcium Scoring in Preventing a First Myocardial Infarction - Consultant360 [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sanders plans to 'change the nature' of campaign after heart attack - New York Post [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Early MI Linked to High Recurrent Events, Mortality - Medscape [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sudden Cardiac Arrest and Ventricular Arrhythmias following first type I Myocardial Infarction in the Contemporary Era - DocWire News [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- E-Cigarette Use and Myocardial Infarction - Physician's Weekly [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Sen. Bernie Sanders had heart attack; chest pains diagnosed as myocardial infarction - KIRO Seattle [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]